Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Change of Registered Address
Regulatory Filings Classification · 1% confidence The document is a short RNS release from the London Stock Exchange providing a corporate administrative announcement (change of registered address). It does not represent a financial report, earnings release, or other specific category, so it falls under the general regulatory announcements bucket.
2026-04-20 English
Result of General Meeting and Change of Name
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an RNS announcement from N4 Pharma PLC regarding the results of a General Meeting where a special resolution to change the company name to Thalia Therapeutics plc was passed. While it mentions the 'Result of General Meeting', it is a regulatory news announcement (RNS) detailing a corporate name change and the outcome of a specific resolution, rather than a comprehensive report of all voting results (DVA) or a full AGM presentation (AGM-R). Given the nature of the announcement as a general regulatory update regarding corporate identity and meeting outcomes, it fits best under the RNS category.
2026-03-17 English
Notice of GM and Proposed Change of Name
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from N4 Pharma PLC regarding a 'Notice of General Meeting' to vote on a proposed company name change. While it mentions a General Meeting, it is an announcement of the meeting and the proposed resolution rather than the proxy materials themselves or the voting results. Given the nature of the announcement regarding corporate structure (name change) and the upcoming meeting, it fits best under the 'Regulatory Filings' (RNS) category as it is a standard regulatory disclosure of corporate activity.
2026-02-27 English
CEO Appointment & Name Change Thalia Therapeutics
Board/Management Information Classification · 1% confidence The document is an official announcement from N4 Pharma PLC regarding a CEO appointment, a strategic shift in business focus, and a proposed company name change. It includes mandatory regulatory disclosures under AIM Rules for Companies (Schedule 2(g)). While it mentions a future General Meeting, the document itself is a corporate announcement of management and strategic changes, which falls under the 'Board/Management Information' category.
2026-02-24 English
Business and Operational Update
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from N4 Pharma PLC providing a 'Business and Operational Update'. It details progress on research collaborations, preclinical study results, intellectual property updates, and anticipated future newsflow. It does not constitute a full financial report, an earnings release, or a specific corporate action like a dividend or share issue. As it is a general corporate update released via a regulatory news service, it falls under the RNS category.
2025-12-18 English
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Results' for N4 Pharma plc for the six months ended 30 June 2025. It contains detailed financial highlights, a Chairman's statement, operational updates, and specific financial data (revenue, loss, cash position). It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.